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end of IL7/placebo treatment was higher in the IL7-treated ani-
mals (122 vs 1/ml, p0.03). All animals were pretransplant cyto-
megalovirus seropositive. One animal died at the end of IL7 treat-
ment; necropsy showed extensive T cell inﬁltration of kidneys and
lungs. In conclusion, IL7 stimulates the expansion of CD4 T cells,
including functional anti-viral cells. Clinical risk:beneﬁt ratio
needs to be evaluated.
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DE NOVO GENERATION OF CD4 T CELLS AGAINST VIRUSES PRESENT
IN THE HOST DURING IMMUNE RECONSTITUTION
Kalina, T.; Lu, H.; Zhao, Z.; Kiem, H.-P.; Storek, J. Fred Hutchinson
Cancer Research Center and University of Washington, Seattle, WA.
Patients after hematopoietic cell transplantation lack naı¨ve T
cells because of insufﬁcient generation of T cells de novo (thymo-
poiesis). Ways to improve de novo generation have recently been
studied, using, e.g., prothymopoietic cytokines or a thymic or-
ganoid (“artiﬁcial thymus”). It is not known whether improved
thymopoiesis might result in more T cells only for pathogens that
are typically absent from the body (e.g., neopathogens like ebola
virus or cleared recall pathogens like measles virus) or also for
pathogens or malignant cells present in the body (e.g., herpesvi-
ruses that infected the host pretransplant or the leukemia that
necessitated hematopoietic cell transplantation). The latter T cells
may be more important, as posttransplant infections due to endog-
enous microorganisms (e.g., herpesviruses) and leukemic relapse
cause major morbidity and mortality. However, T cells recognizing
self-peptides should theoretically be deleted in the thymus by
negative selection. Peptides from the endogenous viruses or leu-
kemic cells might be considered by the thymus as self-peptides, and
T cells speciﬁc for these peptides might be deleted (negatively
selected). We demonstrated in four baboons infected with baboon
cytomegalovirus and baboon lymphocryptovirus (Epstein-Barr vi-
rus-like virus) that after autologous transplantation of yellow ﬂu-
orescent protein (YFP)-marked hematopoietic cells, YFP CD4 T
cells against these viruses were generated de novo. Thus the thymus
generates CD4 T cells against not only pathogens absent from the
host but also pathogens present in the host. This ﬁnding provides
a strong rationale to improve thymopoiesis in hematopoietic cell
transplant recipients.
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CROSS-REACTIVITY OF EPSTEIN BARR VIRUS-SPECIFIC CYTOTOXIC T
LYMPHOCYTES WITH A HLA-C LOCUS ALLELE
Keever-Taylor, C.A.; Ramadan, G.; Orental, R.J.; Davies, B.; Behn, B.;
Margolis, D.A. Medical College of Wisconsin, Milwaukee, WI.
The basis for T cell alloreactivity is thought to be primarily due
to cross-reactivity of antigen-speciﬁc T cells with Major Histo-
compatibility Complex alleles. The cross-reactivity of cytotoxic T
lymphocytes (CTL) from HLA-B8 individuals recognizing the
human herpesvirus IV (HHV4/EBV) FLRGRAYGL epitope en-
coded by the EBNA-3A latency antigen with self peptides pre-
sented on HLA-B4402, B35, and B14 are examples of this phe-
nomenon and may represent the mechanism by which herpes virus
infections augment graft vs host disease, allograft rejection and
autoimmunity. Here we describe an EBV-speciﬁc CTL line pre-
pared from a HLA-B8-negative haplo-identical parental hemato-
poietic progenitor cell donor to restore patient immunity to EBV,
that reacts strongly to non-EBV infected targets from the intended
recipient. The CTL line was primed 2 with donor-derived EBV-
transformed B lymphoblastoid cells lines (BLCL) at a responder:
stimulator ratio of 40:1 that was reduced to 4:1 at wk 3 with the
addition of IL-2 to the culture and was expanded to wk 5 at which
time it was tested for reactivity to donor BLCL and donor and
patient PHA blasts. The line showed potent reactivity to donor
BLCL (66.3% speciﬁc lysis at an effector:target ratio of 50:1), no
reactivity donor PHA blasts but unexpectedly, lysed patient PHA
blasts (41.6% at 50:1) in repeated assays. Screening of the line with
PHA blasts from individuals sharing one or two HLA alleles on the
mismatched patient haplotype revealed that lysis was directed to
HLA-C*0202. Screening of the EBV-CTL line with BLCL targets
from unrelated donors who shared donor HLA alleles but lacked
C*0202 showed that the line was partially HLA-restricted by
HLA-DQ-*0201, B*3701, B*0702, and C*0701. A new line from
the same donor primed for only two weeks with autologous BLCL
at a responder:stimulator ratio of 4:1 also showed strong reactivity
to donor BLCL and patient C*0202 PHA blasts. T cells produc-
ing IFN- in response to irradiated C*0202 PHA blasts were
selected from this line using a MACS column. Further character-
ization of the expanded MACS-selected CTL for EBV speciﬁc
antigen killing and HLA restriction is in progress. These data
further support cross-reactivity to peptide presented on self MHC
as the basis for T cell alloreactivity and illustrate the need for
careful screening of allo-EBV-CTL from HLA mismatched do-
nors with non-EBV infected patient targets to ensure that these
lines are safe to infuse into patients.
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CTL ACTIVITY OF IN VITRO-DERIVED MEMORY T CELLS IS MORE
EFFICIENT THAN NAI¨VE T CELLS IN SYNGENEIC RECIPIENTS IMMEDI-
ATELY FOLLOWING EXPERIMENTAL BMT
Roskos, M.; Levy, R.B. Department of Microbiology and Immunology,
University of Miami School of Medicine, Miami, FL.
We are interested in elucidating how transplanted memory CD8
T cells can contribute to the immune reconstitution of ablatively
conditioned BMT recipients. We have focused our studies on
memory CD8 T cells because they display more rapid, elevated
cytotoxicity compared to naı¨ve CD8 cells, and thus may make more
efﬁcient BMT adjuvants. A homogeneous TCR-transgenic (tg)
memory CD8 T population was generated in vitro and used in a
syngeneic murine BMT model to 1) investigate the homeostatic
proliferation and function of in vitro-derived memory T cells and
2) compare the CTL activity of these memory cells to that of naı¨ve
T cells in the reconstituting host. The in vitro-derived memory T
cell population (TM) was generated using either OT.I-RAG1/
or OT.I-GFP TCR tg mice. Brieﬂy, spleens from OT.I mice were
cultured for 3 days with rmIL-2 and OVA peptide, harvested, and
re-cultured for 2–4 days with rmIL-15. The resultant OT.I cells
expressed CD25lo, CD44hi, CD62L, and Ly6C, indicating a
central memory phenotype. The OT.I cells (1.5  106), together
with T cell-depleted B6 bone marrow (2  106), were transplanted
into 9.0 Gy-conditioned syngeneic recipients. Homeostatic prolif-
eration of TM was assessed by V5, GFP cell numbers in
recipient spleens 4 to 42 days post-BMT. TM expanded during the
ﬁrst 14 days (2 106/spleen) then maintained its number while the
spleen continued to increase for another two weeks. TM cell
number and phenotype remained unchanged90 days post-BMT.
CFSE-labeled OT.I-RAG1/ cells were used to precisely exam-
ine when, during the ﬁrst 2 weeks post-BMT, TM underwent
division. The ﬁrst several divisions were apparent as early as 3 days
post-BMT, and the TM population, as a whole, continued to
divide with 6 divisions observed by day 7. CTL function was
assessed within 14 days and then 28 days post-BMT using OVA-
pulsed targets. TM obtained from recipient spleens 7 days post-
BMT generated a more rapid, elevated CTL response compared to
transplanted naı¨ve OT.I cells (p 
 0.05). TM remained functional
at least 5 weeks post-BMT. In total, these ﬁndings demonstrate
that a homogeneous in vitro-derived memory CD8 T cell popula-
tion can efﬁciently expand and function immediately post-BMT.
Moreover, these memory CD8 T cells exhibit greater cytotoxic
activity compared to naı¨ve CD8 T cells, supporting the notion that
rapidly-generated, in vitro-derived memory CD8 T cells may have
the superior therapeutic potential immediately following BMT.
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RECONSTITUTION OF IMMUNITY TO ADENOVIRUS AFTER PEDIATRIC
BONE MARROW TRANSPLANT
Myers, G.D.; Leen, A.M.; Rooney, C.M.; Heslop, H.E.; Bollard, C.M.
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston,
TX; Department of Virology, Texas Childrens Hospital, Houston, TX;
The Methodist Hospital, Houston, TX.
Adenovirus has been shown to be a signiﬁcant cause of morbidity,
and mortality in the pediatric hematopoietic stem cell transplant
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(HSCT) patient. The degree of immune suppression appears to be
the most important risk factor for development of serious adeno-
viral disease. While withdrawal of immune suppression, and the
use of cidofovir may have some effect in reducing viral load and
hastening immune recovery, these approaches have appreciable
side effects and are not always effective. Little is known about the
reconstitution of immunity to adenovirus after HSCT. Therefore,
in this current study we have prospectively monitored the recovery
of adenovirus cellular immunity in pediatric HSCT patients re-
ceiving matched-related, mismatched related or unrelated donor
grafts. 23 pediatric HSCT patients (age range 14 months-20 years)
were enrolled on this study which aims to monitor viral load and
recovery of cellular immunity to adenovirus post HSCT. We have
developed and validated a real-time PCR (Q-PCR) to obtain a
quantitative measure of viral load. Q-PCR is more sensitive than
semi-quantitative PCR and shows that adenovirus can be detected
(despite the absence of symptoms) in the blood, stool or urine at
rates of up to 70%. 22 patients have30 days follow-up (mean 147
days, range 60–240 days). 18/22 (81%) have had detectable levels
of adenoviral DNA in stool (14/18) or blood (13/18). Positivity in
the stool usually preceded adenovirus detection in the blood. 3
patients were exclusively positive in the blood on one occasion with
low viral copy number (range 650 to 1200 copies/ml). 8 patients
have had multiple blood samples positive for adenovirus DNA
ranging in peak viral copy concentration from 1200 to 92500 cp/ml
(mean 31056 cp/ml). Peak copy number in the stool ranged from
1  103 to 9  109 cp/gram stool. In a preliminary analysis rising
levels appear to correlate with risk of infection. ELISPOT assay
and tetramer analysis for known HLA-restricted adenovirus
epitopes will be used to monitor recovery of adenovirus speciﬁc
T-cells in these patients. The results from this study will, therefore
provide critical information for our forthcoming clinical trial
where we will evaluate if immunity to adenovirus can be improved
by adoptive transfer of adenovirus speciﬁc CTLs generated by
culture with monocytes transduced with an Ad5/35 adenoviral
vector (Leen et al, Blood 2004;104:2432–40).
163
THE EFFECTS OF CYTOTOXIC AND IMMUNOSUPPRESSIVE AGENTS ON
THYMIC RECONSTITUTION
Prockop, S.E.1; O’Reilly, R.J.1; Petrie, H.T.2 1. Memorial Sloan Ket-
tering Cancer Center, New York, NY; 2. University of Miami School of
Medicine, Miami, FL.
One key component of long-term outcome after stem cell trans-
plant (SCT) is successful reconstitution of the immune system. In
this regard, effective reconstitution of antigen-speciﬁc immunity
requires de novo T cell generation. Bone marrow derived progen-
itors seed the thymus and undergo a complex process involving
lineage commitment, proliferation and selection. Coordinated in-
teraction of marrow-derived lymphoid progenitors with thymic
stromal cells is required for successful T lymphopoiesis in the
post-natal thymus. Disruption of the thymic microenvironment
can result in disrupted T cell lymphopoiesis. One cause of pro-
longed defects in generating functional T lymphocytes after SCT
is damage to the thymic microenvironment by radiation or cyto-
toxic therapy. Speciﬁc damage to the thymic microenvironment by
the individual agents used in both myeloablative and non-myeloa-
blative regimens has not been fully evaluated. We have developed
a model system using immunodeﬁcient mice as a platform on
which to assess thymic reconstitution. The thymus of mice deﬁ-
cient for the alpha chain of the IL-7 receptor (IL7R/) can be
reconstituted by the injection of low doses of wild type bone
marrow. The ability to achieve this reconstitution appears to de-
pend on absolute numbers of early intra-thymic precursors, rather
than on total thymic cellularity. Exploiting this model, the ade-
quacy of thymic reconstitution following the administration of
cytotoxic and immunosuppressive agents can be compared to the
thymic reconstitution that occurs in the absence of agents poten-
tially toxic to the thymic stroma. Our model system allows the
evaluation of thymic reconstitution after single agent regimens
insufﬁcient to allow donor cell engraftment in wild type mice. The
effects of several agents on thymic reconstitution will be presented.
In addition we have identiﬁed morphologic consequences of spe-
ciﬁc ablative agents and a phenotype of abnormally developing T
lymphocytes that is speciﬁc to injury from busulfan. It is antici-
pated that this information will lead to strategies to both minimize
delayed immune reconstitution and to augment T cell lymphopoi-
esis post-transplant. In addition, further evaluation of impaired
thymic reconstitution will augment the understanding of lym-
phostromal interactions crucial to normal T cell lymphopoiesis.
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FACTORS UNDERLYING EARLY LYMPHOCYTE RECOVERY AND ASSOCI-
ATED SURVIVAL BENEFIT FOLLOWING AUTOLOGOUS STEM CELL
TRANSPLANT FOR LYMPHOPROLIFERATIVE DISORDERS
Hill, J.M.1; Webber, S.M.2; Fitzmaurice, T.F.1; Cole, B.F.2; Szczepi-
orkowski, Z.M.1; Meehan, K.R.1 1. Dartmouth-Hitchcock Medical Cen-
ter, Lebanon, NH; 2. Dartmouth Medical School, Hanover, NH.
Increasing data now exists to substantiate early absolute lympho-
cyte count (ALC) recovery following both allogeneic and autolo-
gous stem cell transplant as a strong prognostic indicator for
survival, particularly with lymphoproliferative disorders (Myeloma
and Lymphoma). Yet, there is still a paucity of insight into speciﬁc
factors affecting the ALC. Furthermore, the level and time of
optimal lymphocyte recovery reported has varied, ranging between
500–1000 cells/mcl at days 15–25 after transplant. Based on the
above, we performed a retrospective analysis of 59 patients with
Myeloma and Lymphoma (HD and NHL) who had undergone
high-dose chemotherapy and autologous stem cell transplant at
Dartmouth-Hitchcock Medical Center during 2002–2004 to assess
potential factors that might correlate with the ALC. For this
analysis, ALC thresholds of 500 on day 15 (ALC-15) and
1000 on day 25 (ALC-25) post-transplant were included, and
correlated with the following four parameters: 1) age; 2) number of
pre-transplant regimens; 3) dose of CD34 cells/kg recipient in-
fused; 4) 	 IL-2 post-transplant. By both univariate and multivar-
iate analysis, no statistically signiﬁcant correlation was found be-
tween the above four parameters and attainment of ALC-15 500
or ALC-25 1000. A trend toward statistical signiﬁcance was
noted for patients receiving 5  106 CD34 cells/kg or for those
receiving post-transplant IL-2. Given the limitations of a retro-
spective analysis, a follow-up prospective assessment of ALC de-
terminants (both clinical and laboratory) during immune reconsti-
tution after transplant is planned. Hopefully, this will help to
clarify optimal transplant conditions for patients with lymphopro-
liferative disorders as well as to elucidate speciﬁc immunologic
events involved in this early lymphocyte recovery that provide the
basis for a post-transplant survival beneﬁt, presumably via im-
proved immune surveillance against infection and minimal residual
disease.
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THYMIC ACTIVITY OF HUMAN GROWTH HORMONE ON MURINE THY-
MOCYTES: POTENTIAL ROLE IN PROMOTING THYMOPOIESIS FOLLOW-
ING BONE MARROW TRANSPLANT
Welniak, L.A.1; Charter, N.S.1; Murphy, W.J.2 1. University of Ne-
vada School of Medicine, Reno, NV; 2. Nevada Cancer Institute, Reno,
NV.
Thus far, very few agents have been demonstrated to positively
affect thymic function. Many cytokines have been shown to pro-
mote peripheral T cell function but only a select few (i.e. IL-7 and
SCF) have been shown to promote thymopoiesis or T progenitor
cell survival. Most cytokines were meant to exert local effects and
it is often difﬁcult to generate the levels needed after systemic
administration to yield sustained biological effects. Hormones, by
their very nature, are well suited for systemic administration. Neu-
roendocrine hormones such as growth hormone (GH) and prolac-
tin (PRL) have long been associated with effects on immune cell
function. We have shown that administration of recombinant hu-
man GH (rhGH) results in the enhanced recovery of thymopoiesis
following murine syngeneic bone marrow transplants. To explore
the mechanism of action, we investigated the effects of GH on
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